NEW YORK, Feb 1 (Reuters) - Mylan Laboratories Inc. said on Thursday that quarterly profit more than doubled, and reported better-than-expected sales, helped by its generic version of the Ditropan XL ...

The Novo Nordisk A/S (NYSE:NVO) attempt to block Mylan Pharmaceuticals from launching a generic version of its weight-loss drug Wegovy hit a major obstacle as the court ruled in Mylan's favor on key ...

WASHINGTON (CBS.MW) -- Mylan Laboratories said the Federal Trade Commission granted early termination of the Hart-Scott-Rodino waiting period in connection with investor Carl Icahn's plan to buy stock ...

NEW YORK (MarketWatch) -- Mylan Laboratories Inc. said the Food and Drug Administration approved Mylan Pharmaceuticals's Abbreviated New Drug Application for a generic version of Pfizer's Accuretic ...

NEW YORK, Jan 31 (Reuters) - Mylan Laboratories Inc. said on Wednesday it was reorganizing its executive ranks after acquiring a controlling interest in India's Matrix Laboratories Ltd. , and that ...

The Federal Circuit reversed a Patent Trial and Appeal Board (“Board”) decision finding the challenged claims of Sanofi-Aventis’ ’614 patent unpatentable as obvious. Background Mylan petitioned for ...

Billionaire investor Carl Icahn has dropped his $5.39 billion offer to buy Mylan Laboratories Inc. and tendered his shares after regulators opened an investigation of a Mylan pain patch that was ...

BERLIN — German drug maker Merck KGaA announced Sunday that it is selling its generic drug business to Mylan Laboratories Inc. of the U.S. for $6.6 billion. The deal frees Darmstadt-based Merck to ...

The chairman and founder of Mylan Laboratories Inc. is deriding financier Carl Icahn as a stock speculator vowing to complete the contested acquisition of King Pharmaceuticals Inc. despite Icahn's ...

The proposed settlement, which requires a judge’s approval, would resolve a legal battle that began after the company, in 2016, raised the price for two EpiPens to $608 from $100. By Jesus Jiménez The ...

Petition for certiorari denied on October 3, 2011. (1) May diversity jurisdiction be created retroactively after a trial when the plaintiffs’ citizenship was never pleaded or proven? (2) Whether the ...